Scientific and clinical relevance of non-cellular tumor microenvironment components in ovarian cancer chemotherapy resistance

被引:3
作者
Ostrowska-Lesko, Marta [1 ]
Rajtak, Alicja [2 ]
Moreno-Bueno, Gema [3 ,4 ,5 ]
Bobinski, Marcin [2 ]
机构
[1] Med Univ Lublin, Chair & Dept Toxicol, 8B Jaczewskiego St, PL-20090 Lublin, Poland
[2] Med Univ Lublin, Chair & Dept Oncol Gynecol & Gynecol 1, Lublin, Poland
[3] Univ Autonoma Madrid UAM, Biochem Dept, Inst Invest Biomed Sols Morreale IIBm CISC, Madrid, Spain
[4] Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
[5] Fdn MD Anderson Int FMDA, Madrid, Spain
来源
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2024年 / 1879卷 / 01期
关键词
Non-cellular components; Ovarian cancer; Tumor microenvironment; TME; Chemotherapy resistance; CARBONIC-ANHYDRASE-IX; EXTRACELLULAR-MATRIX; TENASCIN-C; CISPLATIN RESISTANCE; PACLITAXEL RESISTANCE; PLATINUM-RESISTANT; PRIMARY SURGERY; LYSYL OXIDASE; OPEN-LABEL; NEOADJUVANT CHEMOTHERAPY;
D O I
10.1016/j.bbcan.2023.189036
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The tumor microenvironment (TME) components play a crucial role in cancer cells' resistance to chemotherapeutic agents. This phenomenon is exceptionally fundamental in patients with ovarian cancer (OvCa), whose outcome depends mainly on their response to chemotherapy. Until now, most reports have focused on the role of cellular components of the TME, while less attention has been paid to the stroma and other non-cellular elements of the TME, which may play an essential role in the therapy resistance. Inhibiting these components could help define new therapeutic targets and potentially restore chemosensitivity. The aim of the present article is both to summarize the knowledge about non-cellular components of the TME in the development of OvCa chemoresistance and to suggest targeting of non-cellular elements of the TME as a valuable strategy to overcome chemoresistance and to develop new therapeutic strategies in OvCA patients.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer
    Neubauer, Hans
    Stefanova, Maya
    Solomayer, Erich
    Meisner, Christoph
    Zwirner, Manfred
    Wallwiener, Diethelm
    Fehm, Tanja
    ANTICANCER RESEARCH, 2008, 28 (2A) : 949 - 955
  • [42] Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients
    Eitan, Ram
    Kushnir, Michal
    Lithwick-Yanai, Gila
    Ben David, Miriam
    Hoshen, Moshe
    Glezerman, Marek
    Hod, Moshe
    Sabah, Gad
    Rosenwald, Shai
    Levavi, Hanoch
    GYNECOLOGIC ONCOLOGY, 2009, 114 (02) : 253 - 259
  • [43] Patient Derived Organoids (PDOs), Extracellular Matrix (ECM), Tumor Microenvironment (TME) and Drug Screening: State of the Art and Clinical Implications of Ovarian Cancer Organoids in the Era of Precision Medicine
    Spagnol, Giulia
    Sensi, Francesca
    De Tommasi, Orazio
    Marchetti, Matteo
    Bonaldo, Giulio
    Xhindoli, Livia
    Noventa, Marco
    Agostini, Marco
    Tozzi, Roberto
    Saccardi, Carlo
    CANCERS, 2023, 15 (07)
  • [44] Clinical effects of debulking surgery combined with neoadjuvant chemotherapy in treating ovarian cancer and its influence on tumor markers and immune function
    Yan, Huijuan
    Wang, Weiwei
    Wang, Shengchao
    Yan, Chunmei
    Zhu, Li
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2024, 40 (11) : 2475 - 2479
  • [45] Tumor necrosis factor α-induced protein 8 expression as a predictor of prognosis and resistance in patients with advanced ovarian cancer treated with neoadjuvant chemotherapy
    Wang, Jing
    Gao, Hongyu
    Liu, Guohui
    Gu, Lina
    Yang, Chang
    Zhang, Fengmin
    Liu, Tianbo
    HUMAN PATHOLOGY, 2018, 82 : 239 - 248
  • [46] Adaptive transcriptomic and immune infiltrate responses in the tumor immune microenvironment following neoadjuvant chemotherapy in high grade serous ovarian cancer reveal novel prognostic associations and activation of pro-tumorigenic pathways
    James, Nicole E.
    Woodman, Morgan
    de la Cruz, Payton
    Eurich, Katrin
    Ozsoy, Melih Arda
    Schorl, Christoph
    Hanley, Linda C.
    Ribeiro, Jennifer R.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [47] Predicting Ovarian Cancer Patients' Clinical Response to Platinum-Based Chemotherapy by Their Tumor Proteomic Signatures
    Yu, Kun-Hsing
    Levine, Douglas A.
    Zhang, Hui
    Chan, Daniel W.
    Zhang, Zhen
    Snyder, Michael
    JOURNAL OF PROTEOME RESEARCH, 2016, 15 (08) : 2455 - 2465
  • [48] Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test)
    Frank Christian Kischkel
    Carina Meyer
    Julia Eich
    Mani Nassir
    Monika Mentze
    Ioana Braicu
    Annette Kopp-Schneider
    Jalid Sehouli
    Journal of Ovarian Research, 10
  • [49] Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test)
    Kischkel, Frank Christian
    Meyer, Carina
    Eich, Julia
    Nassir, Mani
    Mentze, Monika
    Braicu, Ioana
    Kopp-Schneider, Annette
    Sehouli, Jalid
    JOURNAL OF OVARIAN RESEARCH, 2017, 10
  • [50] Is routine omentectomy of grossly normal omentum helpful in surgery for ovarian cancer? A look at the tumor microenvironment and its clinical implications
    Bilbao, Michelle
    Aikins, James K.
    Ostrovsky, Olga
    GYNECOLOGIC ONCOLOGY, 2021, 161 (01) : 78 - 82